Physician profile
Jack A Doah
NPI 1881748135
$1,935.33
in general payments reported to CMS, 2019-2025
28 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $165 · 2021: $30.86 · 2022: $44.81 · 2023: $483 · 2024: $422 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.73 | 2019-2024 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Pfizer INC. | $232.35 | 2019-2025 | |
| Exeltis, USA INC. | $184.81 | 2020-2025 | Slynd |
| Astellas Pharma US INC | $132.65 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $86.81 | 2019-2025 | Aptima |
| Sumitomo Pharma America, INC. | $84.56 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $82.58 | 2023-2024 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $76.73 | 2020-2024 | Bd Max System, Bd Max Instrument |
| Bayer Healthcare Pharmaceuticals INC. | $75.91 | 2019-2025 | |
| Coopersurgical, INC. | $69.24 | 2019-2025 | Paragard T 380a, Endosee |
| Avion Pharmaceuticals | $64.61 | 2019-2022 | |
| Organon LLC | $58.47 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $57.82 | 2023 | |
| Therapeuticsmd, INC. | $53.02 | 2019 | |
| Gynesonics, INC. | $43.15 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.69 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $38.19 | 2023-2024 | Accrufer |
| Allergan, INC. | $37.52 | 2019-2020 | |
| Ethicon US, LLC | $33.36 | 2019 | |
| Daiichi Sankyo INC. | $29.37 | 2020 | |
| Millicent US INC | $28.23 | 2025 | Femlyv |
| Acessa Health INC. | $26.32 | 2019 | |
| Mylan Pharmaceuticals INC. | $25.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.76 | 2019 | |
| Aspira Women'S Health INC | $14.17 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.65 | 2019 | |
| Roche Diagnostics Corporation | $12.80 | 2019 | |
| Mission Pharmacal Company | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Doah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.